6.48
-0.11(-1.67%)
Currency In USD
| Previous Close | 6.59 |
| Open | 6.63 |
| Day High | 6.63 |
| Day Low | 6.29 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 6.2 |
| Volume | 7,290 |
| Average Volume | 203,692 |
| Market Cap | 3.77M |
| PE | -0.56 |
| EPS | -11.5 |
| Moving Average 50 Days | 9.35 |
| Moving Average 200 Days | 891.77 |
| Change | -0.11 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.02 as of June 01, 2025 at a share price of $6.48. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.04 as of June 01, 2025 at a share price of $6.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
GlobeNewswire Inc.
May 20, 2025 10:00 AM GMT
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes f
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
GlobeNewswire Inc.
May 12, 2025 11:34 AM GMT
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back p
Aclarion Welcomes Advocate Health as CLARITY Trial Site
GlobeNewswire Inc.
May 05, 2025 10:00 AM GMT
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to becom